Dr. William J. Provance, DO

Dr. Provance practices at NCH Baker Hospital in Naples, Florida, part of NCH Healthcare System.

Dr. Provance's NPI, 1174517403, was assigned on September 1, 2005. Dr. Provance graduated from Pcom in 1987. Dr. Provance holds Florida license OS12406.

Dr. Provance's primary practice is NCH Baker Hospital, at 350 7th St N, Naples, FL 34102 in Collier County. The practice phone is (239) 624-5000.

Dr. Provance's primary practice is NCH Baker Hospital in Naples, Florida, part of NCH Healthcare System. The medical group on file is NCH Medical Group - Hospitalists. Dmand AI also links Dr. Provance to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Provance practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Provance's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Provance is board certified in gastroenterology by the American Board of Internal Medicine. Dr. Provance is licensed in Florida.

Dmand AI lists acid reflux, colonoscopy, gastroenteritis, gastrointestinal bleeding, intestinal or bowel obstruction, irritable bowel syndrome (IBS) and upper GI endoscopy among the conditions Dr. Provance treats.

CMS data shows 1,113 Medicare services from Dr. Provance across 17 procedure codes in 2024, for 454 Medicare patients. Medicare paid $94,553 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 454 Medicare patients who saw Dr. Provance in 2024. The largest group is 75 to 84, with 216 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Provance's median patient age at 72, with 46% women.

In 2023, Dr. Provance wrote 17 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $269 in total drug cost. In 2022, CMS named 697 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Provance for performance year 2024, reported through an alternative payment model (APM). Dr. Provance accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 251 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Provance, more than 93% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Provance in 2024. Dr. Provance's most frequent co-author is Medjine Jarbath, MD.

Dmand AI links Dr. Provance to 2 clinical trials. Conditions studied include Colitis, Ulcerative and Colitis. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Provance that name 2 trials.

CMS Open Payments shows 544 general payments to Dr. Provance from 31 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 79% of the total. Gilead Sciences, Inc. paid the most, $123,187. It also lists 3 research payments totaling $3,063 from 2018 to 2019, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Provance, most recently CMS Stage 1 2012 in 2011.

Dr. Provance graduated from Pcom in 1987.

Dr. Provance is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.